中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2019, Vol. 48 ›› Issue (6): 542-546.doi: 10.12007/j.issn.0258-4646.2019.06.015

• 论著 • 上一篇    下一篇

乳腺癌根治术患者化疗相关粒细胞减少与预后的关系

王硕1, 郑新宇1,2   

  1. 1. 中国医科大学附属第一医院乳腺外科, 沈阳 110001;
    2. 中国医科大学附属第一医院肿瘤研究所第一研究室, 沈阳 110001
  • 收稿日期:2018-06-23 出版日期:2019-06-30 发布日期:2019-05-29
  • 通讯作者: 郑新宇 E-mail:xyzheng@cmu.edu.cn
  • 作者简介:王硕(1988-),男,医师,硕士.

Prognostic Value of Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Surgery

WANG Shuo1, ZHENG Xinyu1,2   

  1. 1. Department of Breast Surgery, The First Hospital, China Medical University, Shenyang 110001, China;
    2. Lab 1, Cancer Institute, The First Hospital, China Medical University, Shenyang 110001, China
  • Received:2018-06-23 Online:2019-06-30 Published:2019-05-29

摘要: 目的 探讨乳腺癌患者相关粒细胞减少(CIN)与预后的关系。方法 选取2010年9月5日至2011年12月29日中国医科大学附属第一医院乳腺外科327例Ⅰ~Ⅲ期乳腺癌患者,患者均进行根治性手术和化疗,记录患者年龄、病理类型、肿物大小、淋巴结转移、HER-2表达、分期、术式、化疗方案等临床指标;对出现CIN患者与未出现CIN患者的无病生存期进行分析,并对预后因素进行Cox回归分析。结果 327例患者中,162例(49.5%)患者发生CIN,与未出现CIN患者比较,出现CIN患者具有更好预后(χ2=4.022,P=0.045)。198例激素受体阳性患者中,出现CIN患者无病生存期显著高于未出现CIN患者(χ2=9.951,P=0.002)。Cox回归分析显示,CIN不能作为乳腺癌的独立预后因素(P=0.203),但Ⅲ~Ⅳ度CIN可能作为相对独立的预后因素。结论 CIN提示乳腺癌患者预后良好,Ⅲ~Ⅳ度CIN对于预后具有更强的提示作用。

关键词: 乳腺癌, 化疗, 粒细胞减少, 预后

Abstract: Objective The aim of the study was to investigate the prognostic value of chemotherapy-induced neutropenia (CIN) in patients with breast cancer. Methods Patients with stage Ⅰ-Ⅲ breast cancer who were admitted to the First Hospital of China Medical University between 5 September 2010 and 29 December 2011 were enrolled in our study based on predefined inclusion and exclusion criteria. The disease-free survival (DFS) rate of patients with and without CIN was compared. Additionally,patients were divided into hormone receptor (HR) -positive and HR-negative groups;the DFS rate of patients with and without CIN in the HR-positive and HR-negative groups was compared. Cox proportional hazards regression analyses were used to compare the survival rates with clinical and pathologic factors. Results Of 327 patients,CIN occurred in 162 (49.5%) patients;these patients had a better prognosis compared with those without CIN (P=0.045). Moreover,patients with grade Ⅲ-Ⅳ CIN had a better prognosis than patients without CIN (P=0.013). Of the 198 HR-positive patients,the DFS rate was significantly higher in patients with CIN than patients without CIN (P=0.002). Conclusion CIN is a good predictor of prognosis,especially grade Ⅲ-Ⅳ CIN may be regarded as an independent prognostic factor in patients with breast cancer.

Key words: breast cancer, chemotherapy, neutropenia, prognosis

中图分类号: 

  • R453.9
[1] CRAWFORD J,DALE DC,LYMAN GH. Chemotherapy-induced neutropenia-risks,consequences,and new directions for its management[J]. Cancer,2004,100(2):228-237. DOI:10.1002/cncr.11882.
[2] MA RM,CHEN CZ,ZHANG W,et al. Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer[J]. Medicine,2016,95(13):e3240. DOI:10.1097/MD.0000000000003240.
[3] ABRAHAM JE,HILLER L,DORLING L,et al. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities[J]. BMC Med,2015,13:306. DOI:10.1186/s12916-015-0547-5.
[4] OTAKE A,TSUJI D,TAKU K,et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine[J]. Eur J Clin Pharmacol,2017,73(8):1033-1039. DOI:10.1007/s00228-017-2260-0.
[5] WU CF,ANDZINSKI L,KASNITZ N,et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung[J]. Int J Cancer,2015,137(4):837-847. DOI:10.1002/ijc.29444.
[6] BRUNETTO AT,CARDEN CP,MYERSON J,et al. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy[J]. J Thorac Oncol,2010,5(9):1397-1403. DOI:10.1097/Jto.0b013e3181eba7f9.
[7] GOETZ MP,GRADISHAR WJ,ANDERSON BO,et al. Breast cancer,version 3. 2018[J]. J Natl Compr Netw,2019,17(2):118-126. DOI:10.6004/jnccn.2019.0009.
[8] U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common terminology criteria for adverse events (CTCAE) version 4.0[M/OL]. (2010-06-14)[2019-04-12]. http://www.meddramsso.com.
[9] EXTERMANN M,REICH RR,SEHOVIC M. Chemotoxicity recurrence in older patients:risk factors and effectiveness of preventive strategies-a prospective study[J]. Cancer,2015,121(17):2984-2992. DOI:10.1002/cncr.29423.
[10] LOTE H,SHARP A,REDANA S,et al. Febrile neutropenia rates according to body mass index and dose capping in women receiving chemotherapy for early breast cancer[J]. Clin Oncol,2016,28(9):597-603. DOI:10.1016/j.clon.2016.02.003.
[11] KOLACZKOWSKA E,KUBES P. Neutrophil recruitment and function in health and inflammation[J]. Nat Rev Immunol,2013,13(3):159-175. DOI:10.1038/nri3399.
[12] COFFELT SB,WELLENSTEIN MD,DE VISSER KE. Neutrophils in cancer:neutral no more[J]. Nat Rev Cancer,2016,16(7):431-446. DOI:10.1038/nrc.2016.52.
[13] CASBON AJ,REYNAUD D,PARK C,et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils[J]. Proceed Nat Acad Sci USA,2015,112(6):E566-E575. DOI:10.1073/pnas.1424927112.
[14] HANAHAN D,WEINBERG RA. Hallmarks of cancer:the next generation[J]. Cell,2011,144(5):646-674. DOI:10.1016/j.cell.2011.02.013.
[15] USARY J,ZHAO W,DARR D,et al. Predicting drug responsiveness in human cancers using genetically engineered mice[J]. Clin Cancer Res,2013,19(17):4889-4899. DOI:10.1158/1078-0432.CCR-13-0522.
[16] ZHA QB,TANG JH,LI XJ,et al. Prognostic value of chemotherapy-induced amenorrhea in breast cancer:a meta-analysis[J]. Asian Pacific J Cancer Prev,2015,16(14):5939-5944. DOI:10.7314/APJCP.2015.16.14.5939.
[1] 李玉泽, 刘娜, 佟晶, 金蓉, 陈梅, 卑贵光. 动脉自旋标记灌注对足月缺氧缺血性脑病新生儿预后的预测价值[J]. 中国医科大学学报, 2019, 48(9): 812-816.
[2] 段秋艳, 杜秋红, 宋文玲, 苏嘉利, 徐萍. 血清sTWEAK和MMP-9在急性ST段抬高型心肌梗死患者中的表达及其与预后的关系[J]. 中国医科大学学报, 2019, 48(9): 833-836,851.
[3] 孙翠翠, 张斯萌, 温倜, 曲秀娟, 刘云鹏. 晚期非小细胞肺癌肿瘤生长速率与临床病理特征及预后的相关性[J]. 中国医科大学学报, 2019, 48(8): 673-677.
[4] 韩苏, 王传合, 佟菲, 杨丽娜, 崔文佳, 孙志军. 基于倾向性评分匹配法评估钠离子浓度对心力衰竭患者预后的影响[J]. 中国医科大学学报, 2019, 48(8): 714-718.
[5] 程莉莉, 朱美琳, 董有静. 甲强龙联合雷莫司琼治疗全静脉麻醉下乳腺癌改良根治术患者术后恶心呕吐的效果[J]. 中国医科大学学报, 2019, 48(8): 756-759.
[6] 韩苏, 王传合, 佟菲, 杨丽娜, 崔文佳, 孙志军. 性别差异对射血分数中间型心力衰竭患者预后的影响[J]. 中国医科大学学报, 2019, 48(7): 624-628.
[7] 高翔, 刘志宇, 王梁, 戴志红, 汪鑫, 蔡凯. 术前中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对非肌层浸润性膀胱癌的预后评估价值[J]. 中国医科大学学报, 2019, 48(7): 638-642.
[8] 孙华屹, 张宏, 丛进春. 结肠癌根治术患者临床特征与预后的相关性分析[J]. 中国医科大学学报, 2019, 48(7): 660-662.
[9] 董会帅, 范崇渝, 韩云. 肺叶切除与肺段切除治疗肺部磨玻璃结节效果的比较[J]. 中国医科大学学报, 2019, 48(6): 547-550.
[10] 蔡恒, 刘文静, 冯天达, 刘云会. 垂体转移瘤的临床特点及治疗分析:2例病例报道及文献回顾[J]. 中国医科大学学报, 2019, 48(6): 564-567.
[11] 常盼盼, 刘畅, 崇巍. 严重创伤性脑损伤后凝血功能障碍与预后的关系[J]. 中国医科大学学报, 2019, 48(5): 425-429.
[12] 庄莹, 张淑红, 樊伟平, 赵小芳, 孙海燕, 刘爽, 张虎. 乳腺癌中DEAH盒解旋酶16的表达及临床意义[J]. 中国医科大学学报, 2019, 48(4): 305-308.
[13] 蔡存伟, 温媛媛, 李晓燕, 张丽娜. SIAH1核异位表达抑制乳腺癌细胞凋亡的作用机制[J]. 中国医科大学学报, 2019, 48(4): 328-332,337.
[14] 胡明, 张淑红, 陈跟林, 凌存宝, 樊伟平, 孙海燕, 刘爽, 张虎. 泛癌症分析DEAH盒解旋酶16的表达及其预后意义[J]. 中国医科大学学报, 2019, 48(3): 201-204.
[15] 郅重阳, 彭良群, 张占东, 李宁, 刘洪兴, 花亚伟. 倾向评分匹配法探讨预后营养指数与胃癌新辅助化疗后病理完全缓解的相关性[J]. 中国医科大学学报, 2019, 48(3): 245-249,254.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 富苏, 张孟仁. 中药脑复聪对糖尿病大鼠学习记忆能力及海马CA1区胰岛素样生长因子Ⅰ含量的影响[J]. 中国医科大学学报, 2009, 38(9): 677 .
[2] 张颖, 李岩. 消化系统器质性疾病患者抑郁焦虑现状及其影响因素的调查[J]. 中国医科大学学报, 2009, 38(9): 695 .
[3] 万成福, 陈晓光, 马虹, 王俊科. 舒芬太尼对全麻患者罗库溴铵肌松作用的临床观察[J]. 中国医科大学学报, 2009, 38(9): 698 .
[4] 黄波, 李强, 张景国, 韩晓光, 刘君, 何莲, 刘也夫. 胆囊腺瘤癌变过程及免疫表型P53的诊断价值[J]. 中国医科大学学报, 2009, 38(9): 703 .
[5] 王毅, 董静, 刘万洋, 魏薇, 陈杰. 碘缺乏和甲状腺功能减退对大鼠仔鼠海马钙调磷酸酶表达的影响[J]. 中国医科大学学报, 2009, 38(10): 724 .
[6] 邹国良, 仲维莉, 胡健. 缺血后处理对糖尿病大鼠缺血再灌注心肌细胞凋亡的影响[J]. 中国医科大学学报, 2009, 38(10): 745 .
[7] 高洁, 叶新萍, 高妍, 刘飞. 小鼠钟状期牙胚中Frizzled蛋白的表达[J]. 中国医科大学学报, 2009, 38(10): 755 .
[8] 庞晓燕, 张颐. 绝经后妇女绒毛膜癌的临床分析[J]. 中国医科大学学报, 2009, 38(10): 773 .
[9] 初立伟, 杨茂伟, 于江, 王铜浩, 李亚伦. 缺锌对增殖期大鼠生长板软骨细胞凋亡的影响[J]. 中国医科大学学报, 2009, 38(11): 827 .
[10] 赵明芳, 王哲, 魏龙春, 侯科佐, 刘云鹏. 蟾蜍毒素对H22荷瘤小鼠肝癌细胞Mg~(2+)-ATP酶、葡萄糖-6-磷酸酶活性的影响[J]. 中国医科大学学报, 2009, 38(11): 831 .

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA